Adams NP, Bestall JC, Jones PW, Lasserson TJ, Griffiths B, Cates C: Inhaled fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev. 2005, CD003534-3
Bousquet J, Ben-Joseph R, Messonnier M, Alemao E, Gould AL: A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther. 2002, 24 (1): 1-20. 10.1016/S0149-2918(02)85002-0.
Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S, et al: Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol. 1998, 101 (4 Pt 1): 457-63.
Pedersen S, Hansen OR: Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol. 1995, 95 (1 Pt 1): 29-33.
Shapiro G, Bronsky EA, LaForce CF, Mendelson L, Pearlman D, Schwartz RH, et al: Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr. 1998, 132 (6): 976-82. 10.1016/S0022-3476(98)70394-4.
Masoli M, Weatherall M, Holt S, Beasley R: Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax. 2004, 59 (1): 16-20.
Jones SL, Herbison P, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR, et al: Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship. Eur Respir J. 2002, 20 (3): 601-8. 10.1183/09031936.02.00285302.
Chanez P, Karlstrom R, Godard P: High or standard initial dose of budesonide to control mild-to-moderate asthma?. Eur Respir J. 2001, 17 (5): 856-62. 10.1183/09031936.01.17508560.
Tukiainen H, Taivainen A, Majander R, Poussa T, Svahn T, Puolijoki H, et al: Comparison of high and low dose of the inhaled steroid, budesonide, as an initial treatment in newly detected asthma. Respir Med. 2000, 94 (7): 678-83. 10.1053/rmed.2000.0796.
Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al: Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002, 109 (3): 410-8. 10.1067/mai.2002.122635.
Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R: Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Bmj. 2001, 323 (7307): 253-6. 10.1136/bmj.323.7307.253.
Taylor DA, Jensen MW, Kanabar V, Engelstatter R, Steinijans VW, Barnes PJ, et al: A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5'-monophosphate in asthmatic patients. American Journal of Respiratory & Critical Care Medicine. 1999, 160 (1): 237-43.
Gershman NH, Wong HH, Liu JT, Fahy JV: Low- and high-dose fluticasone propionate in asthma; effects during and after treatment. Eur Respir J. 2000, 15 (1): 11-8. 10.1183/09031936.00.15101100.
Swystun VA, Bhagat R, Kalra S, Jennings B, Cockcroft DW: Comparison of 3 different doses of budesonide and placebo on the early asthmatic response to inhaled allergen. J Allergy Clin Immunol. 1998, 102 (3): 363-7. 10.1016/S0091-6749(98)70121-6.
Jatakanon A, Kharitonov S, Lim S, Barnes PJ: Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax. 1999, 54 (2): 108-14. 10.1136/thx.54.2.108.
Dal Negro R, Micheletto C, Tognella S, Turco P, Rossetti A, Cantini L: Assessment of inhaled BDP-dose dependency of exhaled nitric oxide and local and serum eosinophilic markers in steroids-naive nonatopic asthmatics. Allergy. 2003, 58 (10): 1018-22. 10.1034/j.1398-9995.2003.00229.x.
Kharitonov SA, Donnelly LE, Montuschi P, Corradi M, Collins JV, Barnes PJ: Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax. 2002, 57 (10): 889-96. 10.1136/thorax.57.10.889.
Visser MJ, van der Veer E, Postma DS, Arends LR, de Vries TW, Brand PL, et al: Side-effects of fluticasone in asthmatic children: no effects after dose reduction. Eur Respir J. 2004, 24 (3): 420-5. 10.1183/09031936.04.00023904.
Donnelly R, Williams KM, Baker AB, Badcock CA, Day RO, Seale JP: Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study. American Journal of Respiratory & Critical Care Medicine. 1997, 156 (6): 1746-51.
Nielsen LP, Dahl R: Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am J Respir Crit Care Med. 2000, 162 (6): 2053-7.
Visser MJ, Postma DS, Arends LR, de Vries TW, Duiverman EJ, Brand PL: One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Effects on hyperresponsiveness, lung function, and height. Am J Respir Crit Care Med. 2001, 164 (11): 2073-7.
Wilson AM, McFarlane LC, Lipworth BJ: Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics. American Journal of Respiratory & Critical Care Medicine. 1997, 156 (4 Pt 1): 1274-7.
Wilson AM, Sims EJ, Lipworth BJ: Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Clinical Endocrinology. 1999, 50 (3): 329-35. 10.1046/j.1365-2265.1999.00652.x.
Fowler SJ, Orr LC, Wilson AM, Sims EJ, Lipworth BJ: Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. British Journal of Clinical Pharmacology. 2001, 52 (1): 93-5. 10.1046/j.0306-5251.2001.bjcp.1399.x.
Lipworth BJ: Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Archives of Internal Medicine. 1999, 159 (9): 941-55. 10.1001/archinte.159.9.941.
Masoli M, Holt S, Weatherall M, Beasley R: Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J. 2004, 23 (4): 552-8. 10.1183/09031936.04.00076604.
Nathan RA, Li JT, Finn A, Jones R, Payne JE, Wolford JP, et al: A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest. 2000, 118 (2): 296-302. 10.1378/chest.118.2.296.
Raphael GD, Lanier RQ, Baker J, Edwards L, Rickard K, Lincourt WR: A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma. J Allergy Clin Immunol. 1999, 103 (5 Pt 1): 796-803.
Wolfe JD, Selner JC, Mendelson LM, Hampel F, Schaberg A: Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study. Clin Ther. 1996, 18 (4): 635-46. 10.1016/S0149-2918(96)80214-1.
Dahl R, Lundback B, Malo JL, Mazza JA, Nieminen MM, Saarelainen P, et al: A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group. Chest. 1993, 104 (5): 1352-8. 10.1378/chest.104.5.1352.
Hofstra WB, Neijens HJ, Duiverman EJ, Kouwenberg JM, Mulder PG, Kuethe MC, et al: Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma. Pediatr Pulmonol. 2000, 29 (6): 415-23. 10.1002/(SICI)1099-0496(200006)29:6<415::AID-PPUL1>3.0.CO;2-7.
Powell N, Till SJ, Kay AB, Corrigan CJ: The topical glucocorticoids beclomethasone dipropionate and fluticasone propionate inhibit human T-cell allergen-induced production of IL-5, IL-3 and GM-CSF mRNA and protein. Clin Exp Allergy. 2001, 31 (1): 69-76.
Ek A, Larsson K, Siljerud S, Palmberg L: Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy. 1999, 54 (7): 691-9. 10.1034/j.1398-9995.1999.00087.x.
Joseph M, Tonnel AB, Torpier G, Capron A, Arnoux B, Benveniste J: Involvement of immunoglobulin E in the secretory processes of alveolar macrophages from asthmatic patients. J Clin Invest. 1983, 71 (2): 221-30. 10.1172/JCI110762.
Gosset P, Tillie-Leblond I, Oudin S, Parmentier O, Wallaert B, Joseph M, et al: Production of chemokines and proinflammatory and antiinflammatory cytokines by human alveolar macrophages activated by IgE receptors. J Allergy Clin Immunol. 1999, 103 (2 Pt 1): 289-97.
Viksman MY, Bochner BS, Peebles RS, Schleimer RP, Liu MC: Expression of activation markers on alveolar macrophages in allergic asthmatics after endobronchial or whole-lung allergen challenge. Clin Immunol. 2002, 104 (1): 77-85. 10.1006/clim.2002.5233.
Soloperto M, Mattoso VL, Fasoli A, Mattoli S: A bronchial epithelial cell-derived factor in asthma that promotes eosinophil activation and survival as GM-CSF. Am J Physiol. 1991, 260 (6 Pt 1): L530-8.
Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992, 326 (5): 298-304. 10.1056/NEJM199201303260504.
Ackerman V, Marini M, Vittori E, Bellini A, Vassali G, Mattoli S: Detection of cytokines and their cell sources in bronchial biopsy specimens from asthmatic patients. Relationship to atopic status, symptoms, and level of airway hyperresponsiveness. Chest. 1994, 105 (3): 687-96. 10.1378/chest.105.3.687.
Sousa AR, Poston RN, Lane SJ, Nakhosteen JA, Lee TH: Detection of GM-CSF in asthmatic bronchial epithelium and decrease by inhaled corticosteroids. Am Rev Respir Dis. 1993, 147 (6 Pt 1): 1557-61.
Woolley KL, Adelroth E, Woolley MJ, Ellis R, Jordana M, O'Byrne PM: Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma. Am J Respir Crit Care Med. 1995, 151 (6): 1915-24.
Yamashita N, Tashimo H, Ishida H, Kaneko F, Nakano J, Kato H, et al: Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF). Cell Immunol. 2002, 219 (2): 92-7. 10.1016/S0008-8749(02)00565-8.
Anticevich SZ, Hughes JM, Black JL, Armour CL: Induction of human airway hyperresponsiveness by tumour necrosis factor-alpha. Eur J Pharmacol. 1995, 284 (1-2): 221-5. 10.1016/0014-2999(95)00463-U.
Thomas PS, Yates DH, Barnes PJ: Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med. 1995, 152 (1): 76-80.
Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001, 19: 683-765. 10.1146/annurev.immunol.19.1.683.
Schandene L, Alonso-Vega C, Willems F, Gerard C, Delvaux A, Velu T, et al: B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol. 1994, 152 (9): 4368-74.
Takanaski S, Nonaka R, Xing Z, O'Byrne P, Dolovich J, Jordana M: Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. Journal of Experimental Medicine. 1994, 180 (2): 711-715. 10.1084/jem.180.2.711.
John M, Lim S, Seybold J, Jose P, Robichaud A, O'Connor B, et al: Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med. 1998, 157 (1): 256-62.
Stelmach I, Jerzynska J, Kuna P: A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. Clin Exp Allergy. 2002, 32 (2): 264-9. 10.1046/j.1365-2222.2002.01286.x.
Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S: Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol. 1996, 97 (6): 1288-96. 10.1016/S0091-6749(96)70197-5.
Sousa A, Lane S, Nakhosteen J, Lee T, Poston R: Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. Am J Respir Crit Care Med. 1996, 154 (4): 1061-1066.
Yoshida S, Hashimoto S, Nakayama T, Kobayashi T, Koizumi A, Horie T: Elevation of serum soluble tumour necrosis factor (TNF) receptor and IL-1 receptor antagonist levels in bronchial asthma. Clin Exp Immunol. 1996, 106 (1): 73-8. 10.1046/j.1365-2249.1996.d01-808.x.
Watson ML, Smith D, Bourne AD, Thompson RC, Westwick J: Cytokines contribute to airway dysfunction in antigen-challenged guinea pigs: inhibition of airway hyperreactivity, pulmonary eosinophil accumulation, and tumor necrosis factor generation by pretreatment with an interleukin-1 receptor antagonist. Am J Respir Cell Mol Biol. 1993, 8 (4): 365-9.
Sousa AR, Trigg CJ, Lane SJ, Hawksworth R, Nakhosteen JA, Poston RN, et al: Effect of inhaled glucocorticoids on IL-1 beta and IL-1 receptor antagonist (IL-1 ra) expression in asthmatic bronchial epithelium. Thorax. 1997, 52 (5): 407-10. 10.1136/thx.52.5.407.
Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ: Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med. 1999, 159 (4 Pt 1): 1043-51.
Chetta A, Zanini A, Foresi A, Del Donno M, Castagnaro A, D'Ippolito R, et al: Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am J Respir Crit Care Med. 2003, 167 (5): 751-7. 10.1164/rccm.200207-710OC.
Brannan JD, Koskela H, Anderson SD, Chan HK: Budesonide reduces sensitivity and reactivity to inhaled mannitol in asthmatic subjects. Respirology. 2002, 7 (1): 37-44. 10.1046/j.1440-1843.2002.00357.x.
Anderson SD, Brannan J, Spring J, Spalding N, Rodwell LT, Chan K, et al: A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med. 1997, 156 (3 Pt 1): 758-65.
Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR: Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999, 14 (4): 902-7. 10.1034/j.1399-3003.1999.14d29.x.
Bewig B, Barth J: Inhibitory effects of inhaled flunisolide on inflammatory functions of alveolar macrophages. Eur J Clin Pharmacol. 1993, 44 (6): 541-4. 10.1007/BF02440855.
Lipworth BJ, Sims EJ, Das SK, Buck H, Paterson M: Dose-response comparison of budesonide dry powder inhalers using adenosine monophosphate bronchial challenge. Ann Allergy Asthma Immunol. 2005, 94 (6): 675-81. 10.1016/S1081-1206(10)61327-0.
Viksman MY, Liu MC, Bickel CA, Schleimer RP, Bochner BS: Phenotypic analysis of alveolar macrophages and monocytes in allergic airway inflammation. I: Evidence for activation of alveolar macrophages, but not peripheral blood monocytes, in subjects with allergic rhinitis and asthma. Am J Respir Crit Care Med. 1997, 155 (3): 858-63.
Alexis NE, Soukup J, Nierkens S, Becker S: Association between airway hyperreactivity and bronchial macrophage dysfunction in individuals with mild asthma. Am J Physiol Lung Cell Mol Physiol. 2001, 280 (2): L369-75.
Huynh ML, Malcolm KC, Kotaru C, Tilstra JA, Westcott JY, Fadok VA, et al: Defective apoptotic cell phagocytosis attenuates prostaglandin E2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages. Am J Respir Crit Care Med. 2005, 172 (8): 972-9. 10.1164/rccm.200501-035OC.
Nomura H, Sato E, Koyama S, Haniuda M, Kubo K, Nagai S, et al: Histamine stimulates alveolar macrophages to release neutrophil and monocyte chemotactic activity. J Lab Clin Med. 2001, 138 (4): 226-35. 10.1067/mlc.2001.117988.
Marshall BG, Wangoo A, Harrison LI, Young DB, Shaw RJ: Tumour necrosis factor-alpha production in human alveolar macrophages: modulation by inhaled corticosteroid. Eur Respir J. 2000, 15 (4): 764-70. 10.1034/j.1399-3003.2000.15d22.x.
Cotter TP, Hood PP, Costello JF, Sampson AP: Exposure to systemic prednisolone for 4 hours reduces ex vivo synthesis of GM-CSF by bronchoalveolar lavage cells and blood mononuclear cells of mild allergic asthmatics. Clin Exp Allergy. 1999, 29 (12): 1655-62. 10.1046/j.1365-2222.1999.00674.x.
Linden M, Brattsand R: Effects of a corticosteroid, budesonide, on alveolar macrophage and blood monocyte secretion of cytokines: differential sensitivity of GM-CSF, IL-1 beta, and IL-6. Pulm Pharmacol. 1994, 7 (1): 43-7. 10.1006/pulp.1994.1004.
Vecchiarelli A, Siracusa A, Cenci E, Puliti M, Abbritti G: Effect of corticosteroid treatment on interleukin-1 and tumour necrosis factor secretion by monocytes from subjects with asthma. Clin Exp Allergy. 1992, 22 (3): 365-70. 10.1111/j.1365-2222.1992.tb03097.x.
Nakamura Y, Ozaki T, Kamei T, Kawaji K, Banno K, Miki S, et al: Increased granulocyte/macrophage colony-stimulating factor production by mononuclear cells from peripheral blood of patients with bronchial asthma. Am Rev Respir Dis. 1993, 147 (1): 87-91. 10.1164/ajrccm/147.1.87.
Lai CK, Ho SS, Chan CH, Leung R, Lai KN: Gene expression of interleukin-3 and granulocyte macrophage colony-stimulating factor in circulating CD4+ T cells in acute severe asthma. Clin Exp Allergy. 1996, 26 (2): 138-46. 10.1111/j.1365-2222.1996.tb00072.x.
Wang JH, Trigg CJ, Devalia JL, Jordan S, Davies RJ: Effect of inhaled beclomethasone dipropionate on expression of proinflammatory cytokines and activated eosinophils in the bronchial epithelium of patients with mild asthma. J Allergy Clin Immunol. 1994, 94 (6 Pt 1): 1025-34.
Trigg CJ, Manolitsas ND, Wang J, Calderon MA, McAulay A, Jordan SE, et al: Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med. 1994, 150 (1): 17-22.
Amrol DJ, Hagaman DD, Sheller JR, Murray JJ: Soluble CD23 and interleukin-1 receptor antagonist in human asthmatics following antigen challenge. J Asthma. 2005, 42 (1): 73-6. 10.1081/JAS-200044761.
Colavita AM, Hastie AT, Musani AI, Pascual RM, Reinach AJ, Lustine HT, et al: Kinetics of IL-10 production after segmental antigen challenge of atopic asthmatic subjects. J Allergy Clin Immunol. 2000, 106 (5): 880-6. 10.1067/mai.2000.110475.
Olivieri D, Chetta A, Del Donno M, Bertorelli G, Casalini A, Pesci A, et al: Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med. 1997, 155 (6): 1864-71.
Capraz F, Kunter E, Cermik H, Ilvan A, Pocan S: The effect of inhaled budesonide and formoterol on bronchial remodeling and HRCT features in young asthmatics. Lung. 2007, 185 (2): 89-96. 10.1007/s00408-006-0007-2.
Hoshino M, Nakamura Y, Sim JJ, Yamashiro Y, Uchida K, Hosaka K, et al: Inhaled corticosteroid reduced lamina reticularis of the basement membrane by modulation of insulin-like growth factor (IGF)-I expression in bronchial asthma. Clin Exp Allergy. 1998, 28 (5): 568-77. 10.1046/j.1365-2222.1998.00277.x.
Hoshino M, Takahashi M, Takai Y, Sim J: Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol. 1999, 104 (2 Pt 1): 356-63.
Laitinen A, Altraja A, Kampe M, Linden M, Virtanen I, Laitinen LA: Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J Respir Crit Care Med. 1997, 156 (3 Pt 1): 951-8.
Boulet LP, Turcotte H, Laviolette M, Naud F, Bernier MC, Martel S, et al: Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. Influence of inhaled corticosteroids. Am J Respir Crit Care Med. 2000, 162 (4 Pt 1): 1308-13.
Hoshino M, Nakamura Y, Sim JJ, Tomioka H: A comparative study of the effects of ketotifen, disodium cromoglycate, and beclomethasone dipropionate on bronchial mucosa and asthma symptoms in patients with atopic asthma. Respir Med. 1998, 92 (7): 942-50. 10.1016/S0954-6111(98)90194-9.
Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D, et al: Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax. 2002, 57 (4): 309-16. 10.1136/thorax.57.4.309.
Ward C, Reid DW, Orsida BE, Feltis B, Ryan VA, Johns DP, et al: Inter-relationships between airway inflammation, reticular basement membrane thickening and bronchial hyper-reactivity to methacholine in asthma; a systematic bronchoalveolar lavage and airway biopsy analysis. Clin Exp Allergy. 2005, 35 (12): 1565-71. 10.1111/j.1365-2222.2005.02365.x.